Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Healios, Hiroshima Univ. to Collaborate on Cancer Immunotherapy Using Gene-Edited NK Cells
December 22, 2021
- Daiichi Espha Rolls Out Authorized Generics for Artist, Sunrythm
December 21, 2021
- RaQualia Grants Global License for Chronic Pain Drug to Hisamitsu
December 21, 2021
- Takeda’s Vedolizumab Grabs EU Panel Nod for Chronic Pouchitis
December 21, 2021
- Astellas’ Padcev Gets Key European Backing for Bladder Cancer
December 21, 2021
- Shionogi’s Oral COVID-19 Drug Shows High Activity against Omicron
December 21, 2021
- Alnylam Seeks Japan Approval for Vutrisiran for FAP
December 21, 2021
- Mitsubishi Tanabe, 4 Partners Develop AI-Based Protein Crystal Structure Evaluation Technology
December 21, 2021
- Japan’s Dementia/MCI Market to Exceed 400 Billion Yen in 2030: Fuji Keizai
December 21, 2021
- Sosei to Get £5 Million Milestone Payment from GSK as GI Drug Program Progresses
December 21, 2021
- Eisai Snags Rights to Gilead’s JAK Inhibitor Jyseleca in 4 Asian Markets
December 21, 2021
- Biogen Halves US Price Tag on Aduhelm to Improve Patient Access
December 21, 2021
- Astellas to Abolish Pay Structure for Sales Reps, Switching to Company-Wide System Next April
December 20, 2021
- Sosei, Twist Bioscience Hook Up on GPCR Antibodies
December 20, 2021
- Medicago Submits Final Vaccine Data for Canada’s COVID-19 Rolling Review
December 20, 2021
- Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
- Nikhilesh Kalra to Head Up Sanofi’s Japan Consumer Unit from January
December 20, 2021
- Biogen to Challenge European Rejection of Aducanumab
December 20, 2021
- Otsuka Grabs Rights to Kyoto University Spinoff’s iPSC-Derived CAR-T/TCR-T Production Techs
December 17, 2021
- 27 Japan Drug Makers Foresee Stronger Growth in FY2021 vs Initial Forecast: Tally
December 17, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…